Find out more about our subscription products and services by visiting our websites: CorporateHealthcareEnergy
Report Store

Search Within Market Intelligence

Keywords:
Search In
Industry:
Pub Month: From  To 
Price Range ($): Min       Max
 
 
 
 
Free Research Alert
Sign up for updates on the latest research
Email: 
 
 
Call us now on +44 1204 543 529
to speak to an advisor
 

EpiCast Report: Epilepsy - Epidemiology Forecast to 2022

Published: Dec-2012    Report Format:
Report Code: GDHCER003–12
Pharmaceuticals and Healthcare
Single User License
Single User License
$3995
Site License
Site License
$7990
Global License
Global License
$11985
Epilepsy affects 50 million people worldwide each year and is one of the most common neurological conditions in the world (WHO, 2005). Epilepsy is defined as a collection of brain dysfunction disorders characterized by recurrent and unpredictable seizures. The prevalence of epilepsy varies among countries due to a mosaic of economic, political, and social differences.

GlobalData epidemiologists expect that the number of active and lifetime prevalent cases of epilepsy will increase during the forecast period (2012–2022) in the nine markets covered. In 2012, we estimated that there was a total of 17,542,651 active prevalent cases of epilepsy in the nine markets, and GlobalData epidemiologists forecast that by 2022, the number of active prevalent cases will grow to 18,565,967.

A major strength of this analysis is that the forecast methodology was consistent across the nine markets to allow for a meaningful comparison of the patient populations in each country.

Scope

  • The Epilepsy EpiCast Report provides an overview of risk factors and global trends for epilepsy in the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) along with emerging markets—India and China. It includes a 10-year epidemiological forecast of active and lifetime prevalent cases of epilepsy segmented by gender, age, treatment gap, and seizure type (generalized, partial, and unknown).

Reasons To Buy

  • Develop business strategies by understanding the trends shaping and driving the global epilepsy market.
  • Quantify patient populations in the global epilepsy market to improve product development, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the epilepsy gender, age groups, and seizure types (generalized, partial, and unknown) that present the best opportunities for epilepsy therapeutics in each of the markets covered.

Request Sample Pages

First Name*:
Last Name*:
Company / Organization*:
Email Address*:
Country*:
Phone Number*:  
Time Zone:
Comments:
 
© GlobalData 2014. John Carpenter House, 7 Carmelite Street, London EC4 O85.